Evidence map›Paper›PMID 32923142›Full record

ArticleOncoimmunology2020

Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma.

Eliana Marinari, Mathilde Allard, Robin Gustave, Valérie Widmer, Géraldine Philippin, Doron Merkler, Petros Tsantoulis, Valérie Dutoit, Pierre-Yves Dietrich

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Advancements in the Application of scRNA-Seq in Breast Research: A Review.International journal of molecular sciences · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Eliana MarinariLaboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Mathilde AllardLaboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Robin GustaveLaboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Valérie WidmerLaboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Géraldine PhilippinLaboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Doron MerklerDepartment of Pathology and Immunology, Division of Clinical Pathology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Petros TsantoulisCenter for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.ORCID 0000-0003-3613-6682
Valérie DutoitLaboratory of Tumor Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Pierre-Yves DietrichCenter for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
University of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma represents a serious health burden in terms of morbidity and mortality. The prognostic significance of the lymphoid and myeloid infiltrates in glioma is not clearly determined. Moreover, the characterization of different leukocyte subsets in the tumor microenvironment relies mainly on immunohistochemistry observations, and data about their association with prognosis are contradictory. Here, we performed acomprehensive study of both the tumor-infiltrating and circulating immune compartments of patients with high-grade glioma. Nineteen tumor biopsies and 30 PBMC samples were analyzed by RNA sequencing. Validation was performed on The Cancer Genome Atlas (TCGA) RNA sequencing data from glioma and on additional 39 tumor biopsies analyzed by flow cytometry. We identified prognostic tumor and peripheral immune signatures, which associate increased inflammation, immune infiltration and activation with shorter overall survival in high-grade glioma patients. Importantly, we confirmed our observations by flow cytometry analysis and validated the tumor-signature using the TCGA dataset. In addition, both tumor genotype and grade associated with the degree of glioma immune infiltration. Unlike in the majority of cancers, lymphocyte infiltration at the tumor site is anegative prognostic factor in glioma, suggesting the ambivalent pro-tumorigenic role of immune responses in glioma.

Indexed as

Brain NeoplasmsGliomaBiomarkers, TumorHumansInflammationLeukocytes, MononuclearLymphocytesTumor MicroenvironmentBiomarkers, TumorGliomaimmunelymphocytemicroenvironmentprognostic gene signature

Identifiers

PMID32923142
PMCPMC7458651
OpenAlexW3036312533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.